表柔比星联合紫杉醇治疗三阴性乳腺癌临床效果分析

Effectiveness of epirubicin combined with paclitaxel in the treatment of triple-negative breast cancer

目的观察表柔比星联合紫杉醇治疗三阴性乳腺癌的临床效果,以为三阴性乳腺癌治疗方案的选择提供依据。方法选择2016年1月至2018年5月期间渭南市妇幼保健院收治的91例三阴性乳腺癌患者为研究对象,根据随机数表法将患者分为观察组46例和对照组45例,其中对照组患者采用表柔比星治疗,观察组则采用表柔比星联合紫杉醇治疗,以3周为一个周期,总疗程为3~4个周期。治疗结束后,比较两组患者化疗的临床疗效、肿块直径的变化及不良反应发生率,同时采用健康调查简表(SF-36量表)评价生活质量。结果治疗后,观察组患者的治疗总有效率为84.78%,明显高于对照组的62.22%,差异有统计学意义(P<0.05);观察组患者的肿瘤直径为(2.2±0.7)cm,明显低于对照组的(3.1±1.0)cm,差异有统计学意义(P<0.05);两组患者在白细胞及血小板减少、消化道不良反应的发生率方面分别与对照组比较,差异均无统计学意义(P>0.05);观察组患者的SF-36量表中的生理功能(PF)、躯体疼痛(BP)、生理职能(RP)、活力(VT)、情感职能(RE)、精神健康(MH)、总体健康(GH)及社会功能(SF)等评分均明显高于对照组,差异均有统计学意义(P<0.05)。结论表柔比星联合紫杉醇治疗三阴性乳腺癌具有确切的临床效果,不增加不良反应的发生率,且能够有效改善患者的生活质量。

Objective To investigate the clinical effect of epirubicin combined with paclitaxel in the treatment of triple-negative breast cancer, so as to provide basis for choosing treatment plan of triple-negative breast cancer. Methods Ninety-one patients of triple-negative breast cancer treated in Weinan Maternal and Child Health Hospital from January 2016 to May 2018 were selected as the research subjects. According to the random number table method, the patients were divided into observation group(n=46) and control group(n=45). The control group was treated with epirubicin, while the observation group was treated with epirubicin combined with paclitaxel, three weeks as a cycle. The total course of treatment was 3-4 cycles. After treatment, the clinical efficacy, the change of mass diameter,and the incidence of adverse reactions of the two groups were compared, and the quality of life was evaluated by SF-36. Results After chemotherapy, the total effective rate of the observation group(84.78%) was significantly higher than that of the control group(62.22%), and the difference was statistically significant(P<0.05). The diameter of tumors in the observation group was(2.2±0.7) cm, which was significantly lower than(3.1±1.0) cm in the control group(P<0.05).The incidence of leukopenia, thrombocytopenia and gastrointestinal adverse reactions in the observation group showed no significant difference with those in the control group(P>0.05). The scores of physiological function(PF), body pain(BP), role physical(RP), vitality(VT), role emotional(RE), mental health(MH), general health(GH), and social function(SF) of SF-36 scale in the observation group were significantly higher than those of the control group(P<0.05).Conclusion Epirubicin combined with paclitaxel in the treatment of triple-negative breast cancer has a definite clinical effect, does not increase the incidence of adverse reactions, and can effectively improve the quality of life of patients.